Developer docs
API playgroundTry for free, no card

Search company profiles

Aristea Therapeutics

Full company profile

uuid0002abn

Namestring
Aristea Therapeutics
Legal namestring
Aristea Therapeutics, Inc.
Websiteurl
aristeatx.com
Company typeenum
Private
Founded yearint
2018
Short descriptiontext

Aristea Therapeutics is a clinical-stage pharmaceutical company developing novel immunology treatments for orphan diseases. Founded in 2018 and based in San Diego, the pre-revenue private company has raised approximately $117.6 million across three funding rounds.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immunology drug development, orphan disease therapeutics, clinical-stage biopharmaceutical, autoimmune disease treatments, rare disease drug pipeline
Industry1 code
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Clinical-Stage Orphan Immunology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product revenue
TypeOne Time License
Description

Pre-revenue clinical-stage company developing drug candidates for immunology treatments targeting orphan diseases. Revenue would be generated through eventual commercialization of approved therapeutics.

finsmes.com
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aristea Therapeutics is a clinical-stage drug development company developing novel immunology-based therapeutics for patients with orphan autoimmune diseases. The company uses an immunology-based drug development platform to create treatments addressing rare immunology conditions with significant unmet medical need. The company is pre-revenue and has not publicly named specific product candidates.

Differentiator
Functional benefit
Problem solved
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Clinical-stage pharmaceutical company focused on rare diseases, with a lead asset approved for a rare liver condition. Direct comparator on rare-disease commercial strategy and clinical-stage positioning.

2ChemoCentryx
TypeDirect peer
Description

Clinical-stage company developing therapeutics for rare autoimmune and inflammatory diseases (acquired by Amgen in 2022 for $3.7B). Direct comparability to Aristea given shared focus on rare immunology indications and orphan disease commercial models.

TypeEmerging player
Description

Clinical-stage company with rare disease programs including rare metabolic and immunology-adjacent conditions. Partial overlap as a mid-stage rare disease developer comparable in stage to Aristea.

TypeDirect peer
Description

Clinical-stage immunology company (acquired by Pfizer in 2022 for ~$6.7B) that developed therapies for orphan immunology indications including eosinophilic esophagitis. Arena was also a direct investor in Aristea's Series B, reflecting strategic adjacency in immunology pipeline development.

TypeDirect peer
Description

Clinical-stage biotech developing therapies for fibrotic diseases, with significant orphan/rare disease focus. Comparable stage and orphan-disease commercial orientation to Aristea.

TypeBroad incumbent
Description

Commercial-stage rare disease biopharma with multiple approved orphan therapeutics. Comparable focus area and serves as a benchmark for the long-term commercial trajectory Aristea could pursue.

TypeDirect peer
Description

Clinical-stage immunology company developing protein-based therapies for autoimmune and inflammatory diseases (acquired by Vertex in 2024 for ~$4.9B). Direct overlap with Aristea in rare immunology pipeline development.

TypeDirect peer
Description

Clinical-stage immunology company developing small molecule therapies for autoimmune diseases and severe inflammation. Comparable in stage, therapeutic area, and orphan/rare disease orientation.

TypeBroad incumbent
Description

Commercial-stage biopharma focused exclusively on rare and ultra-rare diseases. Represents the scaled rare-disease platform archetype and is a relevant reference point for Aristea's orphan-focused strategy.

10Horizon Therapeutics
TypeBroad incumbent
Description

Established rare and orphan disease-focused biopharma (acquired by Amgen in 2023 for $28B) with multiple approved immunology assets. Representative of the mature, scaled version of Aristea's orphan-immunology thesis and a likely acquirer profile.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aristea Therapeutics

Clinical-Stage Orphan Immunology Therapeuticsaristeatx.com

Aristea Therapeutics is a clinical-stage pharmaceutical company developing novel immunology treatments for orphan diseases. Founded in 2018 and based in San Diego, the pre-revenue private company has raised approximately $117.6 million across three funding rounds.

Aristea Therapeutics firmographics

Firmographics
Name
Aristea Therapeutics
Legal name
Aristea Therapeutics, Inc.
Website
https://aristeatx.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
Aristea Therapeutics is a clinical-stage pharmaceutical company developing novel immunology treatments for orphan diseases. Founded in 2018 and based in San Diego, the pre-revenue private company has raised approximately $117.6 million across three funding rounds.
Ownership category
akta.pro rank

Aristea Therapeutics industry classification

Industry
Product category
Clinical-Stage Orphan Immunology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAE
Rare Immunology, Autoimmune & Autoinflammatory Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Immunology drug development
  • Orphan disease therapeutics
  • Clinical-stage biopharmaceutical
  • Autoimmune disease treatments
  • Rare disease drug pipeline

Where Aristea Therapeutics is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aristea Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical product revenue: Pre-revenue clinical-stage company developing drug candidates for immunology treatments targeting orphan diseases. Revenue would be generated through eventual commercialization of approved therapeutics.

Go-to-market motion1 record

Aristea Therapeutics product offering

Product offering

Core offering

Aristea Therapeutics is a clinical-stage drug development company developing novel immunology-based therapeutics for patients with orphan autoimmune diseases. The company uses an immunology-based drug development platform to create treatments addressing rare immunology conditions with significant unmet medical need. The company is pre-revenue and has not publicly named specific product candidates.

Differentiator

Problem solved

Functional benefit

Companies that use Aristea Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Aristea Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aristea Therapeutics partnerships and signals

Strategic signal

Scale indicators2 records

Aristea Therapeutics competitors and assessment

Company assessment

Direct peers

  • Madrigal Pharmaceuticals: Clinical-stage pharmaceutical company focused on rare diseases, with a lead asset approved for a rare liver condition. Direct comparator on rare-disease commercial strategy and clinical-stage positioning.
  • ChemoCentryx: Clinical-stage company developing therapeutics for rare autoimmune and inflammatory diseases (acquired by Amgen in 2022 for $3.7B). Direct comparability to Aristea given shared focus on rare immunology indications and orphan disease commercial models.
  • Arena Pharmaceuticals: Clinical-stage immunology company (acquired by Pfizer in 2022 for ~$6.7B) that developed therapies for orphan immunology indications including eosinophilic esophagitis. Arena was also a direct investor in Aristea's Series B, reflecting strategic adjacency in immunology pipeline development.
  • Pliant Therapeutics: Clinical-stage biotech developing therapies for fibrotic diseases, with significant orphan/rare disease focus. Comparable stage and orphan-disease commercial orientation to Aristea.
  • Alpine Immune Sciences: Clinical-stage immunology company developing protein-based therapies for autoimmune and inflammatory diseases (acquired by Vertex in 2024 for ~$4.9B). Direct overlap with Aristea in rare immunology pipeline development.
  • Kezar Life Sciences: Clinical-stage immunology company developing small molecule therapies for autoimmune diseases and severe inflammation. Comparable in stage, therapeutic area, and orphan/rare disease orientation.

Emerging players

  • Arcturus Therapeutics: Clinical-stage company with rare disease programs including rare metabolic and immunology-adjacent conditions. Partial overlap as a mid-stage rare disease developer comparable in stage to Aristea.

Broad incumbents

  • BioMarin Pharmaceutical: Commercial-stage rare disease biopharma with multiple approved orphan therapeutics. Comparable focus area and serves as a benchmark for the long-term commercial trajectory Aristea could pursue.
  • Ultragenyx Pharmaceutical: Commercial-stage biopharma focused exclusively on rare and ultra-rare diseases. Represents the scaled rare-disease platform archetype and is a relevant reference point for Aristea's orphan-focused strategy.
  • Horizon Therapeutics: Established rare and orphan disease-focused biopharma (acquired by Amgen in 2023 for $28B) with multiple approved immunology assets. Representative of the mature, scaled version of Aristea's orphan-immunology thesis and a likely acquirer profile.

Market position

Customer concentration

Aristea Therapeutics social profiles

Digital presence

Aristea Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aristea Therapeutics leadership team

Management profile

Number of profiles

Aristea Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aristea Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aristea Therapeutics

What does Aristea Therapeutics do?

Aristea Therapeutics is a clinical-stage drug development company developing novel immunology-based therapeutics for patients with orphan autoimmune diseases. The company uses an immunology-based drug development platform to create treatments addressing rare immunology conditions with significant unmet medical need. The company is pre-revenue and has not publicly named specific product candidates.

Is Aristea Therapeutics a public or private company?

Aristea Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Aristea Therapeutics founded?

Aristea Therapeutics was founded in 2018. It employs 1 to 10 people.

Where is Aristea Therapeutics based?

Aristea Therapeutics is headquartered in San Diego, United States, in the North America region.

How does Aristea Therapeutics make money?

One revenue line is on record: pharmaceutical product revenue.

Who are Aristea Therapeutics's main competitors?

Direct peers on record are Madrigal Pharmaceuticals, ChemoCentryx, Arena Pharmaceuticals, Pliant Therapeutics, Alpine Immune Sciences and Kezar Life Sciences. Arcturus Therapeutics is listed as an emerging player. Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Horizon Therapeutics.

Does Aristea Therapeutics have an API?

No public API is recorded for Aristea Therapeutics.

What industry is Aristea Therapeutics in?

Aristea Therapeutics's product category is Clinical-Stage Orphan Immunology Therapeutics. Its primary akta.pro industry code is HLAIAIAE, Rare Immunology, Autoimmune & Autoinflammatory Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAristea Therapeutics Announces Discontinuation of RIST4721 Development Program and Decision to Dissolve the CompanyAristea Therapeutics announced on February 10, 2023, that it is discontinuing the RIST4721 development program due to safety findings observed in ongoing Phase 2 clinical trials, prioritizing patient safety. Following this decision, the company's Board of Directors determined that the appropriate course of action is to dissolve Aristea Therapeutics after exploring strategic alternatives. The company's CEO stated that while the decision is disappointing for the team and patients, protecting patient safety must remain paramount in drug development.PR NewswireAristea Therapeutics Strengthens its Team with Appointments of Executive Medical Director and Two Clinical Scientists as Clinical Programs ProgressAristea Therapeutics, a clinical-stage immunology drug development company, announced the appointments of three experienced drug development experts to key positions: Himanshu Patel as Executive Medical Director, Jennifer Barnes as Senior Director of Clinical Science, and Walter Frank Eng as Associate Director of Clinical Science. The new hires will support the company's ongoing Phase 2b clinical trials of RIST4721 for palmoplantar pustulosis, hidradenitis suppurativa, familial Mediterranean fever, and Behcet's disease, as well as expand its Dermatology and Rheumatology franchises. The appointments come as Aristea progresses its clinical programs, with the strategic collaboration and option to acquire the company now held by Pfizer following its acquisition of Arena Pharmaceuticals in March 2022.BioSpaceAristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis SuppurativaAristea Therapeutics announced the first patient dosing in its Phase 2a trial of RIST4721, a CXCR2 antagonist, for hidradenitis suppurativa. The trial is randomized, double-blind, placebo-controlled, and recruiting in North America. The company has Phase 2 studies in development for RIST4721 in three additional neutrophil-mediated diseases.PR NewswireAristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis SuppurativaAristea Therapeutics announced the dosing of the first patient in its Phase 2a trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of hidradenitis suppurativa, a chronic inflammatory skin condition affecting 1-4% of the US and European population. The randomized, double-blind, placebo-controlled study is currently recruiting patients in North America and represents the second disease indication for RIST4721, following its lead program in palmoplantar pustulosis. The strategic collaboration and option to acquire Aristea now resides with Pfizer, which acquired Arena Pharmaceuticals in March 2022.socaltech.comAristea Therapeutics Names New Board MembersAristea Therapeutics appointed Mark Gergen and Daniel O'Connell to its board of directors, and named Michael Vincent as an observer. Gergen is CEO of Poseida Therapeutics, O'Connell represents Novo Holdings, and Vincent represents Pfizer.PR NewswireAristea Therapeutics Strengthens its Board of Directors with the Appointment of Three Accomplished Biopharma Leaders From Poseida Therapeutics, Novo Holdings and PfizerAristea Therapeutics announced the appointment of Mark Gergen and Daniel O'Connell to its Board of Directors, and Michael Vincent as a Board Observer, bringing leadership experience from Poseida Therapeutics, Novo Holdings, and Pfizer respectively. The new board members are expected to support the advancement of Aristea's lead molecule RIST4721, currently in Phase 2b clinical development for inflammatory diseases. The timing is notable as Pfizer acquired Arena Pharmaceuticals in March 2022, which now holds the partnership and option to acquire Aristea upon completion of the Phase 2b trial.PR NewswireAristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar PustulosisAristea Therapeutics announced the dosing of the first patient in its Phase 2b trial evaluating RIST4721, a CXCR2 antagonist, for the treatment of palmoplantar pustulosis (PPP), a rare inflammatory skin disorder with no approved therapies in the United States or Europe. The randomized, double-blind, placebo-controlled trial will study the drug over 12 weeks in subjects with moderate to severe PPP and is currently recruiting patients across North America. Aristea also has Phase 2a studies in development for RIST4721 in four additional CXCR2-mediated diseases, including familial Mediterranean fever, Behcet's disease, hidradenitis suppurativa, and inflammatory bowel disease.PR NewswireAristea Therapeutics Announces Key Leadership Appointments to Advance Its Clinical PipelineAristea Therapeutics announced the appointment of Ciara Kennedy as Chair of the Board and Fabio Magrini as Executive Medical Director to advance its clinical pipeline. The company highlighted its recent Series B financing and collaboration with Arena Pharmaceuticals as it develops its lead drug, RIST4721, for inflammatory diseases.PR NewswireAristea Therapeutics to Present at Biotech Showcase 2022 and H.C. Wainwright Bioconnect ConferencesAristea Therapeutics, a clinical-stage immunology company developing therapies for rare inflammatory diseases, announced that President and CEO James Mackay will participate virtually in two investor conferences in January 2022: Biotech Showcase 2022 on January 10 and the H.C. Wainwright Bioconnect Conference from January 10-13. The company will deliver virtual presentations at both conferences, with archived recordings to be made available on the Aristea website following the events. Aristea's lead program RIST4721 is currently in Phase 2b clinical development.PR NewswireAristea Therapeutics to Present at Upcoming Investor ConferencesAristea Therapeutics, a clinical-stage immunology drug development company, announced that President and CEO James Mackay will participate in three investor conferences in September and October 2021. The conferences include the UBS Private Company Conference, Cantor Fitzgerald Healthcare Conference, and Needham Biotech Private Company 1x1 Forum. Archived versions of the virtual presentations will be available on the company's website following the events.